Heterotrimeric G proteins transduce signals from G protein-coupled receptors to regulate numerous signaling events and functions in airway smooth muscle (ASM). In this article, we detail the function and regulation of heterotrimeric G protein signaling in ASM. We further discuss recent advances in the development of experimental tools in the study of G protein signaling, and speculate how these tools might be used in therapeutic strategies that seek to mitigate bronchospasm and airway remodeling that occur in obstructive airway disease.
The traditional view of airway smooth muscle (ASM) described a cell that either contracts or relaxes in order to regulate airway patency and thus airflow. This view implied a similarly simplistic view of the role of heterotrimeric G proteins and G proteincoupled receptors (GPCRs) in ASM: different G proteins and their upstream receptors either promoted or antagonized ASM contraction. Over the past decade, however, ASM has been revealed as a multitasking cell involved in numerous airway functions. Not surprisingly, ASM appears to use the diversity of G protein signaling to accomplish its many functions. This article will provide an overview of G protein signaling in ASM, focusing on the role of G proteins in regulating both ASM contraction and ''synthetic'' functions, under conditions of both normal physiology and disease.
HETEROTRIMERIC G PROTEIN CLASSIFICATION, FUNCTION
Heterotrimeric G proteins consist of a, b, and g subunits and function as transducers of signals from GPCRs. The a subunit is the GTP binding protein, whereas the tightly associated b and g subunits are anchored to the plasma membrane and bind the GDP-bound a subunit with high affinity to constitute the abg heterotrimer. Seventeen different G a , 5 G b , and 12 G g subunits have been identified in humans (1) . The family of G proteins can be divided into four subfamilies (G s , G i/o , G q/11 , and G 12/13 ) based on sequence homology. The G s subfamily includes G s and G olf , and its proteins function as activators of adenylyl cyclase. The G i/o subfamily includes G i1 , G i2 , G i3 , G o1 , G o2 , G z , G t1 , G t2 , and G gust , and functions include the inhibition of adenylyl cyclase. The G q/11 subfamily includes G q , G 11 , G 14 , and G 15/16 , and functions include activation of phospholipase C (PLC).
The G 12/13 subfamily includes G 12 and G 13 , and functions include activation of Rho guanine nucleotide exchange factors (RhoGEFs), Na 1 -H 1 exchangers, and PLC-e (2) .
The mechanism of activation of G proteins, often discussed within the context of the classical transmembrane signaling paradigm of GPCRs, has been established through numerous cell-free and cell-based assays. An agonist-bound GPCR undergoes a conformational change that promotes its association, typically involving the third intracellular loop, with the heterotrimeric G protein (G s in Figure 1 ). The C-terminus of the G alpha subunit is the receptor recognition domain that dictates receptor-G a specificity. Receptor-G a association promotes the release of GDP from G a and binding of GTP. The active GTPbound G a dissociates from G bg and in turn activates an effector molecule (adenylyl cyclase in Figure 1 ). The G bg heterodimer (numerous combinations-although not all possible-of b and g subunits exist) also has the capacity to regulate the activity of various effectors and numerous other signaling elements (discussed below). The intrinsic GTPase activity of G a , which can be modulated by regulators of G protein signaling (RGS) proteins (discussed below), causes the hydrolysis of GTP to GDP to terminate effector activation and promote reconstitution of the membrane-bound G abg trimer.
Although the most recognized functions of the G protein subfamilies reflect the actions of their a subunits, it is now appreciated that the bg subunits mediate numerous functions and greatly expand the capabilities of G proteins (reviewed in Reference 3).
G Q/11 SIGNALING AND FUNCTION IN ASM
Signaling via G q/11 in ASM is of particular interest due to its prominent role in promoting ASM contraction. GPCRs that promote ASM contraction appear to couple primarily to G q . Agonists most efficacious in causing ASM contraction in vivo or ex vivo, including acetylcholine, LTD4, endothelin, and histamine, tend to act on GPCRs typically associated with G q activation (m3 muscarinic acetylcholine receptor [mAChR], cysteinyl leukotriene type 1 receptor [CysLT1R], ET[A/B] receptor, and H1 histamine receptor [H1HR], respectively). Expression of numerous other G q -coupled receptors in ASM has been identified, although their efficacy in increasing airway resistance in vivo or ASM contraction ex vivo can be species dependent (4, 5) . In mice in which the G aq gene is ablated, methacholinestimulated increases in lung resistance as well as tension development in tracheal rings ex vivo is significantly diminished (6) . Whether the residual changes in lung resistance or tension development reflect physiologic coupling to other G q/11 family members, or with G i , is not known. As with G q knockout, ablation of the m3mAChR gene causes a profound reduction in both in vivo and ex vivo ASM contraction stimulated by mAChR agonists (7) . G q activation stimulates the activation of phospholipase Cb, which hydrolyzes phosphoinositol 4,5-bisphosphate (PIP 2 ) into 1,2-diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP 3 ). Both G aq and G bg subunits can activate PLC. Eleven different isoforms of PLC exist and exhibit distinct patterns of regulation, although PLCb1-3 are the major isoforms activated by G q (and G i -derived bg subunits). The net effect of increased IP 3 and DAG levels is to increase intracellular Ca 21 ([Ca 21 ] i ) through release from internal stores and influx from membrane-bound channels (5), and to activate protein kinase C (PKC). Both actions contribute to ASM contraction. The rise in intracellular calcium promotes calcium binding to calmodulin, and calciumcalmodulin complexes with and activates myosin light chain kinase (MLCK). MLCK phosphorylates myosin light chains and enables actin to activate the myosin ATPase activity required for cross-bridge cycling and contraction. Activated PKC is capable of phosphorylating a number of substrates involved in regulating contraction, including calponin and myosin light chain phosphatase (MLCP). PKC-mediated phosphorylation of calponin results in a loss of calponin's ability to inhibit myosin ATPase, whereas PKC-phosphorylated MLCP has reduced ability to dephosphorylate myosin light chain (8, 9) . Pharmacologic inhibition of PKC appears to antagonize G q -mediated contractile signaling in murine ASM ex vivo by affecting elements downstream of the activated G q -coupled receptor (10), whereas up-regulation of PKCa is associated with a hypercontractile phenotype in vivo in mice expressing a peptide inhibitor of G ai2 (11) .
Recent studies have demonstrated an important role of G q signaling in regulating ASM growth. Understanding the mechanisms regulating ASM growth has become an area of intense investigation since the realization that chronic asthma is associated with increases in ASM mass, as evidenced by immunohistochemical analysis of pathology sections and airway biopsies (reviewed in Reference 12) . By reducing airway lumen size and altering the mechanics of airway constriction in response to contractile agonists, increased ASM mass increases both fixed airway resistance and airway reactivity (13) .
Whether increased ASM mass is a precipitating event in the development of asthma or a lagging (yet pathogenic) consequence of airway inflammation and asthma development is unclear. A recent study suggests that airway inflammation is sufficient to increase ASM mass in vivo in the guinea pig (14) . That exaggerated presentation of mitogens to ASM occurs in the inflamed, asthmatic airway is suggested by analyses of bronchoalveolar lavage fluid, which demonstrate increased levels of both growth factors and numerous GPCR agonists as part of the inflammatory milieu (15) (16) (17) .
Both thrombin (capable of activating G q through proteaseactivated receptors [PARs] ) (18, 19) and lysophosphatidic acid (LPA) (EDG receptors) (20) are strong stimulators of cultured ASM DNA synthesis and cell proliferation. These effects appear to be mediated by sufficient activation of the p42/p44 MAPK (via PKC-mediated phosphorylation of Raf-1) and p70S6K pathways, obligate pathways for ASM proliferation (18, 21, 22) , which induce promitogenic transcription factor activation, cyclin D1 induction, and up-regulate the translational machinery necessary for cell cycle progression (23) . Moreover, numerous GPCR agonists including thrombin and LPA, as well as agonists that are minimally mitogenic by themselves (e.g., leukotriene D4, endothelin, histamine, thromboxane, and sphingosine-1-phosphate) have also been shown to potentiate the mitogenic effects of receptor tyrosine kinase signaling (20, 22, (24) (25) (26) . Two recent studies have shed light on mechanisms contributing to this effect. Billington and coworkers (27) demonstrated that thrombin can promote late-phase (.4 h) PI3K (and downstream p70S6K) activity, and that activity appears limiting in the mitogenic effect of epidermal growth factor (EGF). With growth factors providing strong, sustained p42/p44 activity, and the GPCR augmenting PI3K/p70S6K activity, combined RTK and GPCR stimulation results in a greater than additive effect on ASM proliferation. Interestingly, GPCR-mediated activation of PI3K involves G bg subunits, as sequestration of G bg subunits could partially inhibit the cooperative effects of EGF and thrombin on PI3K/p70S6K activity and ASM growth. Moreover, G q appears to be the principal source of these G bg subunits, as the (G q -specific) RGS N-terminal domain of GRK2, but not (G i -inactivating) pertussis toxin, could similarly suppress the cooperative effect of EGF and several GPCR agonists (thrombin, histamine, and thromboxane) on ASM mitogenic signaling and growth (27, 28) .
The role of G q in the cooperative mitogenic signaling by RTKs and GPCRs is further supported by studies from the Groningen group that demonstrate that the synergistic effect of methacholine on PDGF-stimulated growth of guinea pig ASM in culture is mediated by the G q -coupled m3 mAChR and not the G i -coupled m2 mAChR (29) . The physiologic relevance of this finding is supported by a subsequent study demonstrating that the long-acting anticholinergic tiotropium bromide (which is preferentially selective for the m3 mAChR) inhibited the increase in ASM mass caused by repeated allergen challenge in the guinea pig (14) .
G q -dependent activation of PKC and p42/p44 also promotes phosphorylation and activation of phospholipase A2 (PLA2), which contributes to rapid prostaglandin synthesis in ASM cells stimulated with bradykinin (acting on B2 bradykinin receptors) (30) . G q activation in ASM by LPA, endothelin, or carbachol can also promote actin polymerization through a Rho-dependent mechanism (31, 32) , suggesting that effectors other than PLC can be activated by G q in ASM.
G I SIGNALING AND FUNCTION IN ASM
ASM expresses several different GPCRs capable of stimulating G i (24, (33) (34) (35) (36) (37) (38) (39) (40) , although the manner and context in which many of these receptors function are unclear. Members of the G ai family expressed in ASM include G ai1 , G ai2 , and G ai3 (41) . A role for G i in mediating specific cellular signaling or function can be discerned experimentally through the use of pertussis toxin, which catalyzes the ADP-ribosylation of the G ai/o family subunits, thereby locking them in the inactive, GDP-bound state. G ai activation is typically associated with inhibition of G as -stimulated adenylyl cyclase activity and thus reduced cAMP generation. The most prominent and best understood functions of G i in ASM have been deduced from analyses of the m2 muscarinic acetylcholine receptor (m2mAChR). The mAChR agonists acetylcholine (42) and carbachol (43) reduce b-agonist-stimulated cAMP accumulation in a pertussis toxinsensitive manner, implicating G i activation by the m2mAChR. In mice lacking the m2mAChR, forskolin-promoted inhibition of contraction stimulated by a muscarinic receptor agonist is enhanced, this functional gain attributed to relief of G i -dependent antagonism of adenylyl cyclase activity that promotes cAMPdependent PKA activation. Excepting studies showing similar but weaker G i -dependent effects of A1/A3 adenosine (36), somatostatin (40) , and LPA (EDG) receptors (44) , little evidence exists of other G i -coupled receptors antagonizing cAMP accumulation or its relaxant effect on ASM.
Several studies have suggested that G i activation can contribute to increased ASM contraction, presumably via direct PLC activation. G bg subunits are capable of stimulating PLCb1-3 isoforms and thereby stimulating Ca 21 flux, and studies have shown the ability of pertussis toxin to partially reduce carbachol-(45), LPA-(44), A1 adenosine- (46), and chemokine-(33) stimulated phosphoinositide hydrolysis or Ca 21 flux in ASM. The pertussis toxin-mediated reduction of mAChR agonist signaling suggests that both G q and G i , stimulated by the m3mAChR and m2AChR, respectively, can cooperate to regulate [Ca 21 ] i and promote contraction. Pertussis toxin pretreatment also reduces acetylcholine-stimulated contraction of porcine ASM strips ex vivo (47), and tracheal rings from mice lacking the m2mAChR have a lesser tension generation in response to carbachol than do rings from wild-type mice (48) . In contrast to these findings, a recent study by McGraw and colleagues (11) suggests that G ai can function to mitigate ASM contraction ex vivo and in vivo. Mice treated with pertussis toxin, or expressing an inhibitory peptide of G ai2 , exhibit increased MCh-induced airway resistance, whereas G ai2 overexpression attenuated MCh-induced resistance. G ai2 overexpression was associated with a reduction in the PLCb3, and G ai2 inhibition was associated with increased PKCa expression (discussed above), suggesting that the effects on contractile signaling were not direct effects of G ai signaling per se but the consequence of complex regulation of downstream effectors affecting G ai -G aq crosstalk.
A role for G i -coupled receptors in modulating growth in ASM is suggested by studies that demonstrate that pertussis toxin partially inhibits ASM DNA synthesis stimulated by numerous GPCR ligands, including carbachol (activating the m2 mAChR), LPA, sphingosine-1-phosphate, endothelin, and thrombin (12, 24, (49) (50) (51) (52) (53) (54) . However, these effects may be species specific, as inhibition of human ASM proliferation by pertussis toxin in cultures stimulated with any GPCR agonist is typically not observed (27, 28) . The mechanism mediating G i -stimulated growth of ASM is unclear, although actions of both a and bg subunits may be involved. G bg has the potential to stimulate p42/p44 MAPK via activation of PLC and PKC (as described above), and can also mediate p42/p44 activation through Srcdependent transactivation of the EGF receptor (55) . However, none of these mechanisms has been established in ASM. Transactivation of the EGF receptor does not appear to be a mechanism, as it is not induced by thrombin, carbachol, or LPA in human ASM cultures (22, 51) . Moreover, increased p42/p44 MAPK signaling does not appear to mediate the synergistic effect of several GPCR agonists on EGF-stimulated ASM growth (22, 27, 28, 51) .
Other functional consequences of G i activation in ASM include effects on cytoskeleton organization, sensitization of adenylyl cyclase, and chemotaxis. G i is capable of activating Rho through activation of Rho guanine nucleotide exchange factors (GEFs), and in ASM this can mediate both actin polymerization and possibly contractile sensitization (32, 56, 57) . Adenylyl cyclase sensitization, characterized by greater increases in cAMP accumulation by adenylyl cyclase activity in response to forskolin, occurs with chronic treatment of human ASM cultures with carbachol (as well as numerous other agonists of G i -coupled receptors) in a PKC-insensitive, pertussis toxin-sensitive manner (58) . A similar sensitization of adenylyl cyclase occurs in neuronal cells chronically exposed to opioids (contributing to tolerance to morphine), suggesting a compensatory mechanism to counteract persistent G i -coupled receptor activation (59) . Finally, a recent study by Govindaraju and coworkers (33) demonstrates that IL-8 stimulates the chemokine receptors CXCR1 and CXCR2 to promote both ASM cell contraction and migration. CXCR1 and CXCR2 have been widely characterized as pertussis toxin-sensitive receptors, although one study has reported the failure of pertussis toxin to fully inhibit IL-8-stimulated calcium mobilization mediated by CXCR1 activation (60) . CCR7 is also expressed in human ASM and is capable of stimulating Ca 21 mobilization and cell migration (61) 
G S SIGNALING AND FUNCTION IN ASM
G s activates adenylyl cyclase in ASM to increase intracellular cAMP accumulation and PKA activation. PKA plays an important role in regulating ASM contractile state, via mechanisms that: (1) reduce the magnitude of G q -coupled receptor-mediated increases in Ca 21 ; and (2) affect the calcium-dependent regulation of various proteins involved in pro-contractile signaling. Phosphorylation of both G q -coupled receptors and PLC by PKA inhibits GPCR-PLC-mediated PI generation and thus Ca 21 flux, although this mechanism has not been specifically demonstrated in ASM. PKA phosphorylates the IP3 receptor on the sarcoplasmic reticulum, reducing its affinity for IP3 and limiting IP3-stimulated calcium mobilization. PKA phosphorylation of MLCK decreases MLCK's affinity for calcium calmodulin, thus reducing activity and MLC phosphorylation. Myosin light chain phosphatase is phosphorylated on Ser 695 by PKA, which serves to inhibit Rho kinase (ROCK)-dependent phosphorylation of MLCP (potentially inhibiting the inhibition of MLCP) (62) . PKA also phosphorylates K Ca21 channels in ASM, increasing their open-state probability (and therefore K 1 efflux) and promoting hyperpolarization.
A recently appreciated PKA substrate in ASM is heat shock protein 20 (HSP20). When phosphorylated on Ser 16 by either PKA or PKG (63), HSP20 appears capable of relaxing smooth muscle through an ill-defined mechanism possibly involving effects on the cytoskeleton or on actomyosin interaction (64). Dreiza and colleagues (65) demonstrated that treatment with phospho-peptide HSP20 analogs possessing a protein transduction domain peptide can relax vascular smooth muscle preconstricted with serotonin. Preliminary data revealing similar actions in ASM has been reported (P. Komalavilas, unpublished data). Figure 2 depicts the signaling events mediated by G s -coupled receptor activation that serve to antagonize G q -coupled receptor signaling that promotes ASM contraction.
Inhaled b-agonists, acting on G s -coupled b 2 ARs on ASM, are widely used in asthma therapy and are the treatment of choice for acute asthma attacks. Other G s -coupled receptors in ASM include the PGE 2 (36, 67) , and VIP receptors (68) . Each of these receptors has been shown to either signal in ASM cultures or relax contracted ASM ex vivo or in vivo. It is probable that endogenous prostaglandins, prostacyclin, adenosine, and VIP modulate ASM contractile state by activating their cognate G s -coupled receptors on ASM, although the conditions under which such modulation occurs is largely speculative. PGE 2 , acting via an EP2R-and PKA-dependent mechanism, mediates the relaxant effect of the cytokines IL-1b and TNF-a on ASM contractile state (69) .
Although regulation of contraction is the most extensively characterized effect of PKA activity in ASM, other G s -and PKA-dependent effects in ASM include altered transcription of numerous genes that impact airway inflammation and remodeling (70, 71) , inhibition of cell growth (12) , and ion channel gating (72) . In addition, cAMP/PKA-independent signaling by G s -coupled receptors resulting in altered ASM functions has also been reported. Isoproterenol, cholera toxin, and PGE 1 induce actin depolymerization in ASM via two mechanisms, one sensitive to PKA inhibition, another sensitive to Src inhibition (73) . Direct activation of Ca 21 -sensitive K 1 channels can occur via interaction with G as subunits in a manner independent of activation by PKA-mediated phosphorylation of the channel (74) . Relaxation of contracted guinea pig ASM by b-agonist (but not that caused by VIP) lacks sensitivity to pharmacologic inhibitors of PKA (75) , suggesting that some but not all G scoupled receptors can invoke a PKA-independent mechanism of bronchorelaxation.
Finally, a potential downstream effector of G s in ASM is Epac (exchange protein directly activated by cAMP). Epac is a guanine-nucleotide-exchange factor for the small G protein Rap1 that can be activated by cAMP in both a PKA-dependent and -independent manner. In various cell types, Epac has been shown to mediate numerous cellular functions including cell adhesion, insulin secretion, and neurotransmitter release (76) . Although mRNA for Epac1 is expressed in human ASM cultures and the Epac-selective activator 8-pCPT-29OMe-cAMP appears capable of regulating Akt phosphorylation (unpublished observations), a definitive role for Epac signaling in ASM has yet to be identified.
G 12/13 SIGNALING AND FUNCTION IN ASM
Signaling in ASM via activation of the G 12/13 family is poorly understood, and unfortunately very little progress has occurred in recent years to clarify this situation. Rat bronchial smooth muscle tissue has been shown to express G a12 and G a13 protein, and levels are elevated by repeated antigen challenge (77) . ASM expresses numerous GPCRs (including the thomboxane [TP], PAR, and EDG receptors) that are known to couple to G 12/13 . The lack of studies delineating G 12/13 signaling in ASM can be attributed to difficulties in employing molecular approaches to primary ASM cells, which would be useful for selective inhibition of G 12/13 (or other G proteins) activation or of proximal downstream effectors. The complement of effector molecules for G 12 and G 13 is not well established, with the exception of members of a family of guanine nucleotide exchange factors (GEFs) for the small G protein Rho (78) . Rho and Rho kinase are important mediators of ASM actin polymerization (32) , as well as contractile sensitization (79, 80) mediated by numerous agents including cytokines and GPCRs. However, whether G 12/13 activation is involved in these Rho/ Rho kinase-dependent effects in ASM has not been established, whereas in some instances G i (32) and G q (32, 81) have.
PHYSIOLOGIC REGULATION OF HETEROTRIMERIC G PROTEINS
Virtually every protein involved in heterotrimeric G protein signaling, ranging from the upstream activating GPCR to the most downstream signaling molecule in the signal transduction pathway, is subject to regulation via either alterations in its expression, localization, or activity. A comprehensive discussion of such regulation relative to ASM has been previously presented (4) . This review will focus on regulation at the G protein locus and discuss specific findings relevant to ASM.
Heterotrimeric G protein signaling can be affected by regulation of expression of the a subunit. Because G as is expressed in low abundance in ASM (and in most cell types), heterologous overexpression of G as increases basal and b-agoniststimulated cAMP accumulation (58) . Perhaps owing to the difficulty in accurately quantifying G as protein in ASM, few studies have reported modulation of G as expression. Finney and coworkers (82) reported reduced G as expression in rat lung after chronic administration of b-agonist, although expression in ASM was not assessed. Kalavantavanvich and Schramm (83) demonstrated increased G as protein in bovine ASM after treatment with dexamethasone, which was associated with increased b 2 AR expression and an increase in high-affinity isoproterenol binding, suggesting a mechanism of cooperativity by combined b-agonist and steroid treatment, which is currently the preferred therapy for moderate and severe asthma.
Although G ai subunits in most cell types are highly expressed and presumed not limiting in G i -coupled receptor signaling, regulation of their expression in either the lung or ASM strips ex vivo can be induced by cytokine treatment. Intratracheal instillation of IL-1b in the rat induces expression of G ai1 and G ai2 (84) , treatment of rabbit tracheal smooth muscle strips with IL-1b or TNF-a up-regulates G ai2 and G ai3 (85) , whereas exposure to serum from individuals with atopic asthma (86) or rhinovirus (87) increases expression of G ai3 . Human ASM cultures treated with TNF-a exhibit an increase in both G ai2 and G aq expression (88) . The association of the induction of G ai subunits in each of the systems with either a reduction in b-agonist-mediated relaxation or adenylyl cyclase activity implies a role for compartmentalized regulation of adenylyl cyclase by G as and G ai subunits in ASM, and a possible role for increased G ai expression in promoting cytokine-induced hypercontractility in these models. The recent study by McGraw and colleagues (11) confirms the regulatory effect of G ai expression on b-agonist-mediated relaxation of ASM, yet questions the physiologic impact of inflammation-induced up-regulation of G ai subunits. Instead of promoting pro-contractile signaling, increased G ai expression that occurs with inflammation may serve to attenuate such signaling. When mice overexpressing IL-13 (which exhibit increased G ai2 expression) were treated with pertussis toxin, MCh-induced contraction was augmented, suggesting a protective effect of G ai2 induction, perhaps via the a reduction in PLCb3 expression as demonstrated in G ai2 -overexpressing mice.
Regulation of Ga 12/13 expression is not well understood, although as mentioned repeated antigen challenge in a rat model of airway inflammation was shown to cause increases in both G a12 and G a13 expression in bronchial smooth muscle (77) . This up-regulation was associated with increased translocation of RhoA to the plasma membrane, and was speculated to contribute to the enhancement of ACh-induced Ca 21 sensitization of bronchial smooth muscle, and airway hyperresponsiveness (79) in this model.
In numerous cell types, lipid rafts and caveolae have been shown capable of sequestering and compartmentalizing GPCRs, G proteins, and effector molecules, thus serving to form ''signalsomes'' that enable localized signaling as well as another dimension of signaling regulation. Dynamic regulation of both entrée and egress of GPCR signaling molecules and their regulators occurs in caveolae (89) . Although few studies exist examining the role of caveolae in G protein signaling in ASM, Gosens and coworkers (90, 91) and Halayko and colleagues (92) have begun to characterize caveolae structure in ASM via confocal and electron microscopy. Interestingly, caveolae and caveolin-1 protein are much more abundant in ASM cells of the contractile, as opposed to the ''synthetic'' phenotype. Moreover, the b 2 AR and m3mAChR associate with caveolin-rich fractions, whereas the EP2R does not. Lipid raft/caveolae disruption by cholesterol depletion decreases sensitivity of ACh-mediated mobilization of [Ca 21 ] i and contraction of ASM, without affecting maximal ACh-stimulated contraction. These observations suggest that future studies will reveal caveolae as important regulators of G protein signaling in ASM.
As mentioned above, G a subunit GTPase activity is known to be regulated by recently discovered RGS proteins (93) . At least 20 different mammalian RGS proteins have been identified, divided into 9 subfamilies based on sequence similarity (94) . RGS proteins function as GTPase-activating proteins (GAPs), stabilizing a conformation favoring GTP hydrolysis and accelerating the formation of the GDP-bound inactive state of G a subunits, thereby inhibiting Ga signaling. By binding to Ga subunits, they also have the ability to inhibit Ga signaling by steric inhibition of G a -effector interaction. Most RGS proteins exhibit selectivity for both G ai and G aq , although RGS2 exhibits greater selectivity towards G aq in certain cell types (94, 95) . Upregulation of various RGS proteins occurs with heart failure (RGS3 [96] and RGS4 [96, 97] ), addiction (RGS9 [98] ) and neuropathic pain (RGS4 [99] ). Down-regulation of RGS4 in rat hypothalamus was observed with chronic stress or glucocorticoid treatment (100). That RGS proteins are up-regulated under conditions of chronic GPCR activation suggests that their up-regulation serves as a negative feedback mechanism. RGS2 expression appears to be positively regulated by PKA. The RGS promoter contains a cAMP response element, and RGS2 has been shown to be induced by b-agonist or forskolin in cardiac myocytes (101) and osteoblasts (102) (103) (104) . Other modes of RGS regulation, including post-translational modifications and spatiotemporal expression, have been described and represent a means of determining RGS selectively for specific G proteins (94, 105) . To date, no studies have characterized the role of RGS proteins in ASM, although heterologous expression of RGS proteins has been employed to discriminate the role of specific G proteins in ASM functions (see below).
Another means by which G protein signaling can be regulated is by genetic variation (or epigenetic regulation) of any of the heterotrimeric G subunits. Known mutations of G protein subunits that cause striking clinical phenotypes are rare but worthy of note. Inactivating mutations of the gene encoding G as (GNAS1) can cause pseudohypoparathyroidism (PHP), a result of the inability of parathyroid hormone to transduce signals via the G s -coupled PTH receptor (106) . Not surprisingly, other G s -coupled receptor pathways, including those mediated by thyroid-stimulating hormone (TSH), and growth hormone releasing hormone (GHRH), are affected in patients with PHP. Gain-of-function mutations are also observed, in which mutant G as functions as an oncogene to promote pituitary tumors (107) . Similarly, gain-of-function mutations of GNAS1 that occur in McCune-Albright syndrome are associated with multiple endocrinopathies (106) . Mutations in the gene encoding G b3 have been shown to be associated with an obesity interaction on hypertension risk, although the biological significance of G b3 variations is not known (108) . Whether other variations in heterotrimeric G protein subunit genes that have more subtle affects on G protein subunit expression or function have any impact on ASM physiology is not known. Genes encoding G protein subunits tend to be large and possess several introns (unlike those of GPCRs, which are often intronless), rendering them relatively difficult to characterize in large populations. However, given the current rapid rate at which sequencing technology is advancing, it is likely that within 10 years we will have a significant appreciation of how gene variation in G proteins influence GPCR signal transduction, cell physiology, and the prevalence and severity of disease.
NOVEL THERAPEUTIC STRATEGIES FOR TARGETING HETEROTRIMERIC G PROTEIN SIGNALING
Previous reviews have discussed approaches for targeting numerous elements of the GPCR signaling pathways (4, 5) ; here we will focus on novel potential anti-asthma therapeutic strategies that specifically target G proteins in ASM.
Excluding b-agonists, which antagonize contractile G qdependent signaling at multiple pathway elements, most asthma therapies that target ASM contractile signaling do so by either limiting the amount of G q -coupled receptor agonists (steroids) or antagonizing the binding of these agonists (e.g., CysLT1R
and mAChR antagonists). Steroids are arguably a more useful prophylactic given the global suppressive effect on inflammation and the induction of bronchoactive agents, whereas a given receptor antagonist typically blocks only one of many possible pro-contractile agonists. Effective inhibition of G q in ASM would represent an attractive alternative to G q -coupled receptor antagonists in that G q inhibition would effectively block signaling transduced by numerous agonists induced in the inflamed airway.
Anesthetics represent a recently appreciated and intriguing means of regulating G proteins, and their therapeutic utility in asthma via effects on ASM G proteins is suggested by numerous studies by Kai and colleagues (81), Nakayama and colleagues (109, 110) , Sakihara and colleagues (111) , and Streiff and colleagues (112) . Consistent with early observations that volatile anesthetics were an effective means of treating severe bronchospasm and avoiding mechanical ventilation of individuals with asthma, Kai and coworkers demonstrated that halothane Figure 3 . Therapeutic strategies involving GRK functional domains regulating G s and G q signaling. (A) X ray crystal structure of a G aq -GRK2-G bg complex. Top view of the Ga i/q -GRK2-G bg complex as determined by Tesmer and coworkers (121) . The kinase domain of GRK2 is yellow with olive b strands, the RGS homology (RH) domain is purple, and the PH domain is tan, while G aq is cyan with orange b-strands, G b is blue, and G g is green. The three switch regions (I, II, and III) and the N-terminal helix of G aq are red and yellow, respectively. Reprinted by permission from Reference 121. (B) Mechanisms by which expression of GRK2CT and GRK2NT could augment G s -coupled receptor signaling and inhibit G q -coupled receptor signaling, respectively. GRK2CT binds to and sequesters Gbg, thus inhibiting Gbg-mediated translocation of GRK2/3 to membrane/receptor. GRKNT interdicts Gaq association with PLC, thus blocking PLC activation. GRK2NT can also function as a weak GAP. GRK2K22R, a kinase-dead GRK2 mutant containing both GRK2CT and NT domains, has the capacity to both block GRK-mediated desensitization and PLC activation, thus serving as an inhibitor of Gq-coupled receptor signaling and an enhancer of Gs-coupled receptor signaling. b2 5 b2-adreneric receptor; m3 5 m3 muscarinic acetylcholine receptor.
pretreatment reduced ACh-stimulated Ca 21 flux and tension development in canine ASM strips (81) . Subsequent experiments in ASM and in COS-7 cells expressing m3mAChR and G aq suggested that halothane selectively inhibits G aq nucleotide exchange promoted by numerous GPCR agonists (110, 113, 114) . Future studies that uncover the precise means by which anesthetics inhibit agonist-promoted G aq nucleotide exchange could reveal a potentially useful strategy for therapeutic targeting of G q in ASM.
When either microinjected or expressed in cells, peptides corresponding to the C-terminal amino acid sequence of G a subunits have been shown to be effective and selective inhibitors of agonist-induced G protein activation (115, 116) . They are presumed to work by blocking the site on the GPCR that normally binds the G protein. Expression of a C-terminal domain peptide of G aq in cardiac myocytes has been shown to block the up-regulated MAPK activities and reduce the cardiac hypertrophy caused by experimentally-induced pressure overload (117) . Although the efficacy of such peptides has not been tested in models of ASM functions, they represent an attractive therapeutic possibility should a suitable system for in vivo intracellular delivery be developed.
Another similar and potentially useful therapeutic approach involves expression or delivery of RGS proteins in/to ASM. RGS proteins that inhibit G aq and possibly G ai could be effective inhibitors of acetylcholine-stimulated contraction, and of contraction stimulated or augmented by the numerous GPCR agonists that are induced in the airway by inflammation. Moreover, ASM growth and other synthetic functions augmented by G aq -or G ai -coupled receptors could be similarly antagonized. As noted above, the utility of using RGS proteins in inhibiting G aq signaling in ASM was demonstrated recently in Kong and colleagues (28) in which expression of the RGS-like N-terminus of GRK2 was able to mitigate the mitogenic effects of multiple agonists of G q -coupled receptors. Conceptually more appealing yet untested to date in ASM is the (holo-) GRK2 protein lacking kinase activity (GRK2-K220R [118] ). This protein includes both the RGS N-terminal domain and the G bg -binding C terminal domain of GRK2, thus enabling inhibition of both G aq signaling and G bg effects. Because G bg effects include activation of pro-mitogenic PI3K activity (27, 28) and enhancement of GRK-mediated desensitization of the b 2 AR, kinase-dead GRK2 could conceivably shift the competitive balance of GPCR signaling by inhibiting the deleterious (pro-contractile, pro-mitogenic) signaling of Gq, while augmenting the (pro-relaxant, anti-mitogenic) signaling of the G s -coupled b 2 AR (Figure 3) .
In addition, because other RGS proteins appear to have greater GAP activity than that exhibited by GRK2NT, they have the potential to be more efficacious inhibitors of G aq -mediated functions in cells.
Advantages of the commonly used GPCR ligands as therapeutics include their ease of targeted delivery to the airway and ability to bind their targets at the cell surface. The majority of the strategies discussed above for targeting G proteins, with the exception of anesthetics, require a means of delivery that will enable hydrophobic peptide/protein accumulation or expression within the cell. Presently, chimeric proteins possessing protein transfection domains (119, 120) , liposome or nanoparticle carriers, and viral systems represent promising delivery systems for peptides or proteins, as well as siRNA, to lung cells. The inclusion of targeting moieties to delivery vehicles, or cell-specific transcription/translational control elements within delivered genes, can help target drugs/genes to ASM. The hope is that by the time these delivery systems come of age, we will have sufficient understanding of the regulation of G protein signaling in ASM, and will have identified molecules that antagonize signaling events mediating bronchospasm, cell growth and migration, and immunomodulatory functions with sufficient efficacy and selectivity.
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